文献速递临床试验与 GCP基础与转化研究

非贫血孕妇口服铁补充与妊娠期糖尿病风险的双盲随机对照试验

A randomized controlled double-blinded trial to assess the risk of gestational diabetes mellitus in non-anemic pregnant women who receive oral iron supplementation.
PubMed 文献 · Trials · 2026-07-28

本研究为随机双盲平行对照试验,在印度非贫血初孕妇中比较每日口服元素铁60 mg与30 mg对妊娠期糖尿病(GDM)发病率的影响。每臂纳入800例,于孕中期补充12周,主要比较GDM发病率,并评估β细胞功能及未甲基化胰岛素启动子DNA。结果将为印度孕期普遍补铁指南提供证据。

要点

  • 非贫血孕妇每日60 mg元素铁与30 mg相比,GDM风险差异尚待试验结果。
  • 研究同时评估β细胞功能及未甲基化胰岛素启动子DNA作为β细胞损伤标志。
  • 结果可能影响印度普遍补铁政策是否应针对低铁状态孕妇。

核心结论

  • 该试验旨在明确非贫血孕妇每日口服60 mg与30 mg元素铁对GDM发病率的影响,结果尚未报告。

研究设计与样本

  • 随机、平行组、双盲临床试验,每臂纳入800例非贫血初孕妇。
  • 干预为孕中期每日口服元素铁60 mg或30 mg,持续12周。

关键数值与推荐

  • 主要结局为GDM发病率,比较60 mg/天与30 mg/天两组。
  • 次要结局包括OGTT评估胰岛素分泌动力学及循环游离DNA中未甲基化胰岛素启动子DNA定量。

临床怎么用

  • 试验结果将为印度国家指南中孕期普遍口服铁补充是否适用于所有孕妇提供证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnant women in India are routinely prescribed oral iron supplements as part of the national Anemia Mukt Bharat (AMB) program for anemia control. In women with iron-deficiency anemia, the benefits of iron supplementation during pregnancy, both for the mother and child, are very clear. In non-anemic pregnant women, however, the benefits of iron supplementation vis-à-vis associated risks that have been reported have not been studied adequately. Studies have suggested that iron may impair insulin secretion, thus increasing the risk of gestational diabetes mellitus (GDM). PRIMARY OBJECTIVE: To determine the incidence of GDM among non-anemic pregnant women receiving 60 mg/day of elemental iron as oral supplementation, compared with those receiving 30 mg/day. SECONDARY OBJECTIVES: To assess beta-cell functional capacity and quantify unmethylated insulin promoter DNA (a sensitive and specific marker of beta-cell damage) in blood samples from the two study groups. METHODS: This study is a randomized, parallel-group, double-blinded clinical trial, with 800 non-anemic primigravidae in each arm. One arm will receive oral supplementation at a dose of 60 mg per day (as per current national guidelines), while the other arm will receive 30 mg per day, for a duration of 12 weeks in the second trimester. The incidence of GDM in the two arms will be compared. Insulin secretion kinetics will be assessed using an oral glucose tolerance test (OGTT) done at the end of the intervention. Additionally, the unmethylated insulin promoter DNA in circulating free DNA (a marker of beta-cell damage) will be quantified in both arms. DISCUSSION: The study's findings will provide important evidence relevant to the current national guidelines in India on universal oral iron supplementation during pregnancy. The results are expected to inform future policy decisions on whether universal supplementation for all pregnant women is appropriate or whether it should be targeted to those with low iron status. TRIAL REGISTRATION: CTRI/2024/04/065301 [registered on 05/04/2024]-trial registered prospectively.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Varghese J, Jacob M, Venkatesan P, et al. A randomized controlled double-blinded trial to assess the risk of gestational diabetes mellitus in non-anemic pregnant women who receive oral iron supplementation. Trials. 2026. PMID: 42919408. doi:10.1186/s13063-026-09468-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。